The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Feb. 04, 2014
Filed:
Sep. 04, 2009
Bin Cao, Bedminster, NJ (US);
Vieroslava Gurunian, Allamuchy, NJ (US);
Sathapana Kongsamut, Madison, NJ (US);
Raymond W. Kosley, Jr., Bridgewater, NJ (US);
Rosy Sher, Bridgewater, NJ (US);
Ryan E. Hartung, Bridgewater, NJ (US);
Bin Cao, Bedminster, NJ (US);
Vieroslava Gurunian, Allamuchy, NJ (US);
Sathapana Kongsamut, Madison, NJ (US);
Raymond W. Kosley, Jr., Bridgewater, NJ (US);
Rosy Sher, Bridgewater, NJ (US);
Ryan E. Hartung, Bridgewater, NJ (US);
Sanofi, Paris, FR;
Abstract
The present invention relates to a series of substituted dihydro and tetrahydro oxazolopyrimidinones, specifically, to a series of 2-substituted-2,3-dihydro-oxazolo[3,2-a]pyrimidin-7-ones and 2-substituted-2,3,5,6-tetra-hydro-oxazolo[3,2-a]pyrimidin-7-ones of formula (I): Wherein p, n, X, Y, R, R, R, R, R, R, Rand Rare as defined herein. This invention also relates to methods of making these compounds including novel intermediates. The compounds of this invention are modulators of metabotropic glutamate receptors (mGluR), particularly, mGluR2 receptor. Therefore, the compounds of this invention are useful as pharmaceutical agents, especially in the treatment and/or prevention of a variety of central nervous system disorders (CNS), including but not limited to acute and chronic neurodegenerative conditions, psychoses, convulsions, anxiety, depression, migraine, pain, sleep disorders and emesis.